SEC Filing Summary: India Globalization Capital, Inc. (IGC Pharma, Inc.)
Business Context and Reporting Period
This Form 8-K Current Report, dated March 24, 2011, details a material definitive agreement and the creation of a direct financial obligation by India Globalization Capital, Inc. (IGC). The filing reports a restructuring of an existing debt obligation with the Steven M. Oliveira 1998 Charitable Remainder Unitrust ("Oliveira").
Key Financial Metrics and Transaction Details
- Debt Restructuring: IGC exchanged an outstanding unsecured promissory note (the "2009 Note") with a principal amount of $2,120,000 for a new unsecured promissory note (the "New Oliveira Note") of the same principal amount.
- Equity Issuance: As part of the exchange, IGC issued 368,339 shares of common stock to Oliveira.
- Interest Rate: The New Oliveira Note bears interest at 30% per annum.
- Repayment Terms: The note is repayable in 12 monthly installments of $206,673.00 (principal and interest), commencing in April 2011, with a maturity date of March 24, 2012.
- Payment Flexibility: IGC has the sole option to make payments in cash or freely tradable common stock.
- Liquidity Impact: The transaction generated no cash proceeds for the Company.
Material Changes Versus Prior Period
The New Oliveira Note introduces significant changes compared to the 2009 Note it replaced:
- Interest: The 2009 Note was non-interest bearing; the New Note carries a 30% annual interest rate.
- Payment Schedule: The 2009 Note was due in full on October 5, 2010, with no interim payments. The New Note requires monthly installments.
- Payment Method: The 2009 Note required cash payment only. The New Note allows IGC to pay in cash or stock.
- Prepayment: The 2009 Note had mandatory prepayment provisions tied to future financings. The New Note has no mandatory prepayment provisions and allows voluntary prepayment without penalty.
- Late Fees: The New Note imposes a late fee of $20,000 per month (pro-rated) for missed payments, payable in cash or stock, a provision absent in the 2009 Note.
Guidance, Risks, and Contingencies
- Stockholder Approval: IGC has registered 1,570,000 shares for issuance to Oliveira. If the Company needs to issue shares in excess of this amount to satisfy the Note, it must obtain stockholder approval pursuant to NYSE Amex Rules.
- Valuation of Stock Payments: If IGC elects to pay in stock, the share price is calculated as the lower of 95% of the 5-day VWAP prior to the payment date or 100% of the VWAP on the payment date.
- Regulatory Status: The securities were issued under exemptions from registration (Section 3(a)(9) and Section 4(2) of the Securities Act of 1933) as a private exchange with an accredited investor.
- Default Risk: Failure to make payments triggers a significant monthly late fee and accelerates the maturity of the note.
Investor Verification Checklist
- Verify the current cash position of IGC to assess its ability to meet the $206,673 monthly cash payment obligations if it chooses not to pay in stock.
- Confirm the current trading volume and price of IGC common stock to evaluate the potential dilution impact if payments are made in shares.
- Review the Company's capitalization table to determine if the 1,570,000 share registration limit will be exceeded before the March 2012 maturity.
- Check for any subsequent filings regarding stockholder approval for additional share issuances.
- Assess the Company's history of meeting payment deadlines given the high interest rate and late fee structure.